| Registry | NCT05079880 |
|---|---|
| Status | Unknown |
| Phase | Phase 2 |
| Study type | Interventional; randomized, sequential, masking: double, treatment |
| Enrollment | 60 (Estimated) |
| Sponsor | Tunis University (Other) |
| Conditions | Laparoscopic Cholecystectomy |
| Interventions | 300 mg of caffeine citrate infusion, Placebo (Drug) |
| Dates | start 2021-08-15, primary completion 2021-10-15 (estimated), completion 2021-10-30 (estimated), first posted 2021-10-15, last updated 2021-10-15 |
| Locations | 1 site in Tunisia |
Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for Laparoscopic Cholecystectomy All trials of 300 mg of caffeine citrate infusion All trials of Placebo
A faster emergence from general anesthesia has a double medico-economic impact by reducing the risks of complications and optimizing the performance of surgical units. No drug has been retained for its ability to actively accelerate anesthetic emergence by antagonizing hypnotics. Thus, the aim of this study was to examine the effect of caffeine on the time to emerge from sevoflurane anesthesia for laparoscopic cholecystectomy.
| Arm | Type | Interventions | Description |
|---|---|---|---|
| GC group | Experimental | Drug: 300 mg of caffeine citrate infusion | received 300 mg of caffeine citrate infusion |
| GS group | Placebo comparator | Drug: Placebo | Equivalent saline infusion |
Sex: All, ages: 18 Years to any
Inclusion Criteria: * American society of Anesthesiologists (ASA) I and II patients, aged older than 18 years old and scheduled for laparoscopic cholecystectomy Exclusion Criteria: * Patient with an allergy to caffeine citrate and analgesics used during postoperative period, those with severe renal or hepatic failure, those who refused to participate in addition to patient with heart rhythm disorder, seizure disorder, hypertension, alcoholic or psychiatric illness
| Facility | City | Country | Status |
|---|---|---|---|
| Habib Thameur Hospital | Tunis | Tunisia | Recruiting |